California SJS Lawsuits: Legal Options After a Suspected Drug Reaction

Understanding SJS/TEN and Why Medication Cases Happen

Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are rare, severe conditions that can begin with flu-like symptoms and progress to painful rash, blistering, skin detachment, and mucosal involvement (for example, eyes, mouth, and genital areas). Many patients require hospitalization and may be treated in intensive care or burn units. Medical references describing these features include the Mayo Clinic and the National Organization for Rare Disorders (NORD).

From a legal perspective, suspected drug-induced SJS/TEN cases often turn on whether safety risks were adequately evaluated, monitored, and communicated, especially through FDA-approved labeling and other safety communications, and whether different warnings or clinical decisions could have prevented or reduced the harm.

Common Drugs and Risk Factors: Why It Is Usually Case-Specific

Medical literature and drug labeling for some medications discuss SJS/TEN risk, but identifying a single suspect drug is not always straightforward. People may have multiple prescriptions, recent infections, or other potential triggers. A careful timeline review (when each medication started, dose changes, stop dates, symptom onset) is frequently critical, and causation usually requires qualified medical expert analysis.

Early records often matter most (urgent care or ER notes, dermatology consults, inpatient notes, discharge summary, and ophthalmology records), because they may document initial symptoms and contemporaneous suspicion about triggers.

Who May Be Responsible in a California SJS/TEN Case?

Depending on the facts and the defendants involved, potential targets of a claim may include:

• Manufacturers: Claims commonly focus on warnings, labeling, and pharmacovigilance. For California’s approach to prescription-drug strict liability design-defect limits, see Brown v. Superior Court. For failure-to-warn principles in California, see Carlin v. Superior Court.
• Generic vs. brand-name issues: Some claims involving generic drug labeling face federal preemption constraints. See PLIVA, Inc. v. Mensing and Mutual Pharmaceutical Co. v. Bartlett. Separately, California recognizes certain circumstances where a brand-name manufacturer may owe a duty regarding labeling relied upon even when the patient took a generic equivalent. See T.H. v. Novartis Pharmaceuticals Corp.. These issues are highly fact-dependent.
• Distributors and others in the supply chain: Depending on the theory and product, additional entities may be implicated, though the analysis varies by facts and legal doctrine.
• Pharmacies and healthcare providers: Typically involved only in narrower circumstances (for example, dispensing errors or alleged malpractice). Medical malpractice claims have separate standards and deadlines under California law (see Code of Civil Procedure Section 340.5).

Core Legal Theories (and Important Limits) in California Drug-Injury Litigation

Failure to warn / inadequate warnings

A claim may allege inadequate warnings about SJS/TEN risk, early symptoms, higher-risk populations, interactions, or when to stop the medication and seek emergency care. California authority addressing prescription-drug warning duties includes Carlin v. Superior Court. Whether a warning was adequate often depends on the state of knowledge and labeling at the time of use.

Design defect (often limited for prescription drugs)

In California, strict-liability design-defect claims against prescription drug manufacturers are generally limited by the policy recognized in Brown v. Superior Court. Depending on the product and theory, plaintiffs may still explore other avenues (such as warning-based theories or, in some contexts, negligence theories), but viability is medication-specific and sensitive to regulatory and preemption issues.

Manufacturing defect

If evidence supports that a particular lot or batch deviated from specifications or was contaminated, a manufacturing-defect theory may be investigated.

Negligence / misrepresentation (fact-dependent)

Negligence claims may overlap with product-liability theories and can focus on alleged unreasonable conduct (for example, safety monitoring or label-update practices). Some cases also examine whether marketing or communications allegedly minimized severe risks. These claims are evidence-driven and may be limited by federal law depending on how they are framed.

What Usually Must Be Proven: Causation, Warning Impact, and Damages

Although every case is different, many SJS/TEN lawsuits turn on:

• Medical causation: Whether a specific drug exposure was a substantial factor in causing SJS/TEN. This frequently involves expert analysis, differential diagnosis, timing, and evaluation of alternative causes (including infections).
• Warning adequacy and impact: Whether a different warning or different communication of the risk would have changed prescribing, monitoring, or patient decision-making.
• Damages: SJS/TEN can involve extensive losses, including hospitalization, ICU or burn-unit care, infection complications, vision injury, scarring, chronic pain, psychological harm, lost income, and long-term disability. Wrongful-death damages are also possible in appropriate cases.

Evidence That Commonly Matters

If you are able to do so (or a family member can assist), the following often becomes important in evaluating a claim:

• Complete pharmacy records (all fills, prescribers, dosing instructions)
• Medication containers and written drug information you received (Medication Guide or leaflet)
• ER records and triage notes describing early symptoms and suspected triggers
• Dermatology consults, biopsy results (if done), and final discharge summary
• Ophthalmology records (acute and follow-up)
• Photos documenting progression (date and time if possible)
• Lab work and infectious workups
• Any adverse-event report submitted to the FDA’s MedWatch program. See https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program.

Where a Case Might Be Filed (and MDL Possibilities)

Depending on the drug and circumstances, cases may be filed in California state court, California federal court, or transferred into a federal multidistrict litigation (MDL) if many similar federal cases exist nationwide for the same product. The MDL process is governed by 28 U.S.C. Section 1407. MDLs generally centralize certain pretrial proceedings; what happens next depends on the specific MDL and case posture.

Timing: California Deadlines Can Vary by Claim Type

California has strict time limits, and the correct deadline depends on the claim type, defendants, and discovery issues. For example, many personal injury and wrongful death actions are subject to a two-year limitations period (see Code of Civil Procedure Section 335.1), while medical malpractice claims have distinct timing rules (see Code of Civil Procedure Section 340.5). Claims involving public entities can require an administrative claim much sooner (see Government Code Section 911.2).

Because SJS/TEN cases often involve rapid hospitalization and complicated medication histories, it is wise to get claim-specific legal advice promptly to evaluate deadlines and preserve evidence.

Immediate Steps After Suspected Drug-Induced SJS/TEN

• Seek emergency care immediately. SJS/TEN can worsen quickly; see Mayo Clinic.
• Ask clinicians to document suspected trigger(s) and the timeline of symptom onset.
• Write down every medication and supplement (including start or stop dates if known) and any recent illness or infection.
• Save containers, packaging, and paperwork (including any Medication Guide or insert you received).

FAQ

Can I sue if the label already mentioned SJS/TEN?

Sometimes. A case-specific review may focus on whether the warning was sufficiently prominent and specific, whether it reached the right audience (for example, prescribers and patients), and whether additional warnings, contraindications, or instructions could have changed prescribing or monitoring decisions.

Do I have a case if I took a generic drug in California?

Generic-drug claims can raise federal preemption issues (see PLIVA, Inc. v. Mensing and Mutual Pharmaceutical Co. v. Bartlett). California law may recognize certain duty theories involving brand-name labeling in specific circumstances (see T.H. v. Novartis Pharmaceuticals Corp.). The analysis is highly fact-dependent.

Is this a medical malpractice case or a product-liability case?

It depends. Some matters are primarily product cases (warnings, manufacturing issues), while others may involve healthcare-provider conduct under medical malpractice standards and deadlines (see Code of Civil Procedure Section 340.5). Many situations require evaluating both angles.

How long do I have to file in California?

Deadlines vary by claim type and facts. Many personal injury and wrongful death claims use a two-year limitations period (see Code of Civil Procedure Section 335.1), medical malpractice has different rules (see Code of Civil Procedure Section 340.5), and claims involving public entities can require an administrative claim much sooner (see Government Code Section 911.2).

Talk to a California Attorney About an SJS/TEN Medication Claim

To discuss a case-specific review of your records, timeline, and potential defendants, reach out here: Contact us.

California disclaimer: This post is general information, not legal advice, and does not create an attorney-client relationship. Deadlines and liability rules can differ based on the claim type (including medical malpractice and claims involving public entities), the defendants, and when the injury reasonably should have been discovered. If you believe you may have SJS/TEN, seek emergency medical care immediately; for legal guidance about your specific situation, consult a qualified California attorney promptly.